Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pelikan Technologies Inc.

This article was originally published in Start Up

Executive Summary

Pelikan Technologies Inc. hopes to eliminate the procedural drawbacks that deter diabetics from frequent monitoring with an integrated system that combines electronic lancing and glucose monitoring in one step.
Advertisement

Related Content

Where are They Now? Checking in on Three Glucose-Monitoring Start-Ups
Pelikan Swoops in on the Big Four
Pelikan Swoops in on the Big Four
Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?
Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
In Hospital Equipment It's Goodbye Agilent, Hello Philips-Andover
In Hospital Equipment It's Goodbye Agilent, Hello Philips-Andover

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel